7.1 Diabetes Management & Counseling

Assessing the Patient: Type 1 vs Type 2 Diabetes

Before building a care plan, confirm which disease you are managing, because the consequences of treatment errors differ completely. Type 1 diabetes mellitus (T1DM) is an autoimmune destruction of pancreatic beta cells; patients are insulin-dependent from diagnosis and stopping insulin — even for one day during illness — risks diabetic ketoacidosis (DKA). Type 2 diabetes mellitus (T2DM) is progressive insulin resistance with relative insulin deficiency; it is managed stepwise, and insulin is usually a late addition.

Diagnostic Criteria

Diagnosis (ADA/WHO-aligned) rests on any one of the following, confirmed on a separate day if the patient is asymptomatic:

• HbA1c ≥6.5% (48 mmol/mol), using a standardized assay
• Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) after ≥8 hours fasting
• 2-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) during a 75 g oral glucose tolerance test
• Random plasma glucose ≥11.1 mmol/L with classic symptoms (polyuria, polydipsia, weight loss)

Remember that HbA1c is unreliable with hemoglobinopathies, recent transfusion, iron-deficiency treatment, or hemolysis — highly relevant in the Gulf region where sickle-cell trait and thalassemia trait are common. Use plasma glucose criteria in those patients.

Individualizing Glycemic Targets

The general HbA1c target is <7% for most non-pregnant adults. Individualize:

• Tighter (~<6.5%): younger patients, short disease duration, no cardiovascular disease, long life expectancy, when achievable without significant hypoglycemia.
• Looser (~<8%): advanced age, frailty, established vascular complications, severe hypoglycemia history, limited life expectancy.

Typical self-monitoring targets paired with an HbA1c <7% are fasting/pre-prandial glucose of 4.4–7.2 mmol/L and peak post-prandial <10 mmol/L.

Guideline-Directed Sequencing

Metformin remains first-line pharmacotherapy for T2DM alongside structured lifestyle intervention (weight loss of 5–10%, ≥150 minutes/week of activity). Check renal function before starting: do not initiate if eGFR <30 mL/min/1.73 m² (contraindicated below 30; review dose between 30–45), and counsel about gastrointestinal upset and long-term vitamin B12 monitoring.

Modern ADA/ESC sequencing selects the add-on by comorbidity, not just HbA1c:

• Established ASCVD or high cardiovascular risk → add a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular outcome benefit (e.g., liraglutide, semaglutide, dulaglutide; empagliflozin, canagliflozin, dapagliflozin).
• Heart failure or chronic kidney disease (albuminuria) → SGLT2 inhibitor preferred, independent of glucose control.
• Weight reduction a priority → GLP-1 receptor agonist or SGLT2 inhibitor; avoid sulfonylureas, thiazolidinediones, and insulin where possible.
• Cost-driven → sulfonylurea or pioglitazone are inexpensive but carry hypoglycemia/weight or fluid-retention trade-offs.

Insulin Initiation, Titration, and Injection Technique

When T2DM patients need insulin (typically HbA1c well above target on two or three agents, or symptomatic hyperglycemia), start basal insulin 10 units once daily (or 0.1–0.2 units/kg), titrating by 2 units every 3 days against the fasting glucose target. Continue metformin; review sulfonylureas once prandial insulin is added. T1DM patients need basal-bolus regimens from the start.

Counsel on injection technique at every supply: rotate sites within one region (abdomen absorbs fastest, then arms, thighs, buttocks), keep injections at least 1 cm apart, use 4 mm pen needles for most adults, never reuse needles, and palpate sites for lipohypertrophy — injecting into lumpy tissue causes erratic absorption and unexplained glucose swings.

Monitoring, Hypoglycemia, and Driving

Self-monitoring of blood glucose (SMBG) is essential for anyone on insulin or sulfonylureas; continuous glucose monitoring (CGM) is increasingly standard in T1DM and insulin-treated T2DM, with a time-in-range (3.9–10 mmol/L) goal above 70%. Teach a written hypoglycemia action plan: below 4.0 mmol/L, take 15–20 g fast-acting carbohydrate, recheck in 15 minutes, repeat if still low, then follow with a starchy snack if the next meal is distant. Prescribe glucagon for patients at risk of severe hypoglycemia and train a family member to give it. For driving (DVLA-style rules adopted by many Gulf licensing authorities): insulin- and sulfonylurea-treated patients should test before driving and every 2 hours on long journeys, keep glucose above 5 mmol/L ('five to drive'), carry fast-acting carbohydrate in the vehicle, and never drive while hypoglycemic.

Sick-Day Rules, Foot Care, and Ramadan

Teach the SADMANS mnemonic for acute dehydrating illness (vomiting, diarrhea, fever): temporarily stop SGLT2 inhibitors, ACE inhibitors, Diuretics, Metformin, ARBs, NSAIDs, and Sulfonylureas until eating and drinking normally for 24–48 hours. Insulin is never stopped — doses often need increasing during illness with more frequent glucose and ketone monitoring.

Foot care counseling: inspect feet daily, wash and dry between toes, never walk barefoot, check shoes for foreign objects, moisturize dry skin but not between toes, and attend at least annual foot screening with monofilament sensation and pulse checks. Any new ulcer, blister, or color change warrants same-week referral.

Ramadan counseling is core UAE practice. Stratify risk pre-Ramadan (ideally 6–8 weeks before): T1DM, pregnant patients, recent DKA or severe hypoglycemia, and advanced CKD are very high risk and should be advised against fasting or fast only with close supervision. Practical adjustments include moving the morning sulfonylurea dose to iftar and reducing or omitting the daytime dose, continuing metformin/DPP-4 inhibitors largely unchanged, reducing pre-sunset basal or premixed insulin doses by roughly 15–30%, and increasing glucose monitoring — which does not break the fast. Instruct patients to break the fast immediately if glucose falls below 3.9 mmol/L, rises above 16.7 mmol/L, or if symptoms of hypoglycemia or dehydration appear.